Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

636 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.
Eroglu Z, Holmen SL, Chen Q, Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley I, Liu JKC, Chen YA, Najjar YG, Karreth FA, Abate-Daga D, Glitza IC, Sosman JA, Sondak VK, Bosenberg M, Herlyn M, Atkins MB, Kluger H, Margolin K, Forsyth PA, Davies MA, Smalley KSM. Eroglu Z, et al. Among authors: davies ma. Pigment Cell Melanoma Res. 2019 May;32(3):458-469. doi: 10.1111/pcmr.12771. Epub 2019 Feb 19. Pigment Cell Melanoma Res. 2019. PMID: 30712316 Free PMC article.
Phosphatidylinositol-3-kinase as a therapeutic target in melanoma.
Aziz SA, Davies M, Pick E, Zito C, Jilaveanu L, Camp RL, Rimm DL, Kluger Y, Kluger HM. Aziz SA, et al. Clin Cancer Res. 2009 May 1;15(9):3029-36. doi: 10.1158/1078-0432.CCR-08-2768. Epub 2009 Apr 21. Clin Cancer Res. 2009. PMID: 19383818 Free PMC article.
In vitro studies of dasatinib, its targets and predictors of sensitivity.
Jilaveanu LB, Zito CR, Aziz SA, Chakraborty A, Davies MA, Camp RL, Rimm DL, Dudek A, Sznol M, Kluger HM. Jilaveanu LB, et al. Among authors: davies ma. Pigment Cell Melanoma Res. 2011 Apr;24(2):386-9. doi: 10.1111/j.1755-148X.2011.00835.x. Pigment Cell Melanoma Res. 2011. PMID: 21320292 Free PMC article. No abstract available.
Targeted therapy for brain metastases.
Davies MA. Davies MA. Adv Pharmacol. 2012;65:109-42. doi: 10.1016/B978-0-12-397927-8.00005-1. Adv Pharmacol. 2012. PMID: 22959025 Review.
Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma.
Alrwas A, Papadopoulos NE, Cain S, Patel SP, Kim KB, Deburr TL, Bassett R Jr, Hwu WJ, Bedikian AY, Davies MA, Woodman SE, Hwu P. Alrwas A, et al. Among authors: davies ma. Melanoma Res. 2014 Aug;24(4):342-8. doi: 10.1097/CMR.0000000000000062. Melanoma Res. 2014. PMID: 24743052 Free PMC article. Clinical Trial.
mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.
Damsky W, Micevic G, Meeth K, Muthusamy V, Curley DP, Santhanakrishnan M, Erdelyi I, Platt JT, Huang L, Theodosakis N, Zaidi MR, Tighe S, Davies MA, Dankort D, McMahon M, Merlino G, Bardeesy N, Bosenberg M. Damsky W, et al. Among authors: davies ma. Cancer Cell. 2015 Jan 12;27(1):41-56. doi: 10.1016/j.ccell.2014.11.014. Cancer Cell. 2015. PMID: 25584893 Free PMC article.
636 results